AcelRx Pharmaceuticals

375 articles with AcelRx Pharmaceuticals

• AcelRx Pharmaceuticals to Hold Fourth Quarter 2012 Financial Results Conference Call and Webcast on March 12, 2013

  3/7/2013

• AcelRx Pharmaceuticals Pain Treatment Meets Late-Stage Study Goal

  3/6/2013

• AcelRx Pharmaceuticals to Present at Two Upcoming Investor Conferences

  2/27/2013

• AcelRx Pharmaceuticals Provides Clinical Trial Updates

  2/19/2013

• AcelRx Pharmaceuticals Appoints Adrian Adams to Board of Directors as Chairman

  2/12/2013

• AcelRx Pharmaceuticals Announces Exercise of Option to Purchase Additional Shares

  12/17/2012

• AcelRx Pharmaceuticals to Present Top-Line Data From Phase 3 Study of Sufentanil NanoTab&#0174 PCA System vs. IV PCA Morphine at the 66th Annual PostGraduate Assembly in Anesthesiology held in New York City

  12/14/2012

• AcelRx Pharmaceuticals Announces Pricing of Public Offering of Common Stock

  12/7/2012

• AcelRx Pharmaceuticals Announces Proposed Public Offering of Common Stock

  12/5/2012

• AcelRx Pharmaceuticals to Present at the Piper Jaffray 24th Annual Healthcare Conference

  11/21/2012

• AcelRx Pharmaceuticals Meets Primary Endpoint in Phase 3 Non-Inferiority Study

  11/15/2012

• AcelRx Pharmaceuticals Reports Third Quarter 2012 Financial Results

  11/7/2012

• AcelRx Pharmaceuticals Doses the First Patients in ARX-04 Phase 2 Clinical Study

  11/5/2012

• AcelRx Pharmaceuticals to Hold Third Quarter 2012 Financial Results Conference Call and Webcast on November 6, 2012

  11/1/2012

• AcelRx Pharmaceuticals Receives Notice of Eligibility for Centralized Review From European Medicines Agency for the Sufentanil NanoTab&#0174 PCA System

  10/3/2012

• AcelRx Pharmaceuticals Hires Mike A. Royal, M.D. as Chief, Clinical Affairs

  9/18/2012

• AcelRx Pharmaceuticals to Present at the UBS Global Life Sciences Conference

  9/11/2012

• AcelRx Pharmaceuticals Receives Fourth and Fifth U.S. Patents for Small-Volume Oral Transmucosal Dosage Forms

  8/29/2012

• AcelRx Pharmaceuticals to Present at Three Upcoming Investor Conferences

  8/24/2012

• AcelRx Pharmaceuticals Initiates Third Phase 3 Clinical Trial for ARX-01, the Sufentanil NanoTab&#0174 PCA System, for the Treatment of Post-Operative Pain

  8/23/2012